We noticed that DTYMK expression was the lowest in C3 subtypes (inflammatory, high Th1 and Th17 infiltration) of human cancers, especially in BLCA, BRCA, ESCA, LUAD, LUSC, OV, PAAD, prostate adenocarcinoma (PRAD), READ, SARC, and STAD. This evidence concerns the gene DTYMK and prostate adenocarcinoma.